Trial
NCT02953509
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
The Leukemia and Lymphoma Society
Condition
Non Hodgkin Lymphoma
Intervention
Magrolimab
Why stopped
Study terminated early due to the magrolimab program discontinuation.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-29